𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prospect of the treatment of human gastric ulcers with orally administered epidermal growth factor

✍ Scribed by Itoh, Makoto ;Imai, Shinpei ;Joh, Takashi ;Takeuchi, Toshihiko


Publisher
Springer-Verlag
Year
1993
Tongue
English
Weight
380 KB
Volume
28
Category
Article
ISSN
0435-1339

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


First clinical experience of orally acti
✍ Maria Giulia Zampino; Elena Magni; Cristian Massacesi; Alberto Zaniboni; Angelo πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 148 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as second‐line treatment for advanced colorectal cancer (CRC). Gefitinib combined with FOLFOX6 (oxaliplatin plus folinic acid

Decreased mitogenic response to epiderma
✍ David L. Crowe; Kenneth J. Tsang πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 163 KB πŸ‘ 1 views

## Abstract Growth factor receptors of the tyrosine kinase family regulate proliferation of a variety of cell types. In some human cancers, the epidermal growth factor receptor (EGFR) and its ligands often are overexpressed, leading to both constitutive and autocrine activation. Intracellular signa